Eldred Rock Partners LLC Sells 15,323 Shares of Novo Nordisk A/S (NYSE:NVO)

Eldred Rock Partners LLC decreased its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 16.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 75,851 shares of the company’s stock after selling 15,323 shares during the quarter. Novo Nordisk A/S accounts for approximately 2.3% of Eldred Rock Partners LLC’s portfolio, making the stock its 24th largest position. Eldred Rock Partners LLC’s holdings in Novo Nordisk A/S were worth $6,865,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Annex Advisory Services LLC increased its stake in Novo Nordisk A/S by 4.5% in the fourth quarter. Annex Advisory Services LLC now owns 5,052 shares of the company’s stock valued at $435,000 after acquiring an additional 219 shares during the last quarter. My Legacy Advisors LLC raised its holdings in shares of Novo Nordisk A/S by 2.9% during the 4th quarter. My Legacy Advisors LLC now owns 7,029 shares of the company’s stock valued at $583,000 after buying an additional 201 shares in the last quarter. Liberty One Investment Management LLC lifted its position in Novo Nordisk A/S by 27.9% in the 4th quarter. Liberty One Investment Management LLC now owns 2,373 shares of the company’s stock worth $204,000 after buying an additional 517 shares during the last quarter. Romano Brothers AND Company boosted its stake in Novo Nordisk A/S by 12.0% in the fourth quarter. Romano Brothers AND Company now owns 6,328 shares of the company’s stock worth $544,000 after buying an additional 680 shares in the last quarter. Finally, Aaron Wealth Advisors LLC grew its position in Novo Nordisk A/S by 6.9% during the fourth quarter. Aaron Wealth Advisors LLC now owns 21,572 shares of the company’s stock valued at $1,856,000 after acquiring an additional 1,396 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Price Performance

NVO opened at $78.74 on Monday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The stock has a market capitalization of $353.33 billion, a PE ratio of 25.48, a price-to-earnings-growth ratio of 0.92 and a beta of 0.45. The stock’s 50 day moving average price is $97.76 and its 200-day moving average price is $117.05. Novo Nordisk A/S has a 52-week low of $78.17 and a 52-week high of $148.15.

Analyst Ratings Changes

NVO has been the subject of a number of research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. BMO Capital Markets lowered their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Finally, StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Buy” and an average target price of $140.20.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.